FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000366372> ?p ?o ?g. }

• W2000366372 endingPage "125" @default.
• W2000366372 startingPage "121" @default.
• W2000366372 abstract "Sickle cell anemia is a chronic inflammatory disease characterized by an increased production of proinflammatory cytokines including tumor necrosis factor-alpha. Hydroxyurea, by decreasing the polymerization of hemoglobin, reduces inflammatory states. The effect of the genetic polymorphisms of sickle cell patients on tumor necrosis factor-alpha levels remains unknown. The aim of this study was to investigate the association of tumor necrosis factor-alpha levels with β-globin haplotypes and the use of hydroxyurea. A cross-sectional study was performed of 67 patients with sickle cell anemia diagnosed at steady-state in a referral hospital in Fortaleza, Ceará, Brazil. A group of 26 healthy individuals was used as control. βS haplotype analysis was performed by restriction fragment length polymorphism-polymerase chain reaction. The tumor necrosis factor- alpha levels were measured by the enzyme-linked immunosorbent assay test. Laboratory data (complete blood count and fetal hemoglobin) and information regarding the use of hydroxyurea were obtained from medical records. Statistical analysis was performed using R software with the Kruskal-Wallis and Mann–Whitney tests. Statistical significance was established for p-values < 0.05 for all analyses. The mean age of the participants was 35.48 years. Patients with sickle cell anemia had significantly higher tumor necrosis factor-alpha levels than controls (p-values < 0.0001). Tumor necrosis factor-alpha levels were lower in sickle cell anemia patients who were receiving hydroxyurea treatment than those who were not (p-value = 0.1249). Sickle cell anemia patients with Bantu/n genotype had significantly higher levels than patients with the Bantu/Benin genotype (p-value = 0.0021). In summary, βS-globin haplotypes, but not hydroxyurea therapy, have a role in modulating tumor necrosis factor-alpha levels in sickle cell anemia adults at steady-state. Many previous studies have investigated prognosis and inflammatory states in sickle cell anemia patients, but the discovery that tumor necrosis factor-alpha levels vary according to the genetic polymorphism of the patient is a new finding. © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved." @default.
• W2000366372 created "2016-06-24" @default.
• W2000366372 creator A5016476003 @default.
• W2000366372 creator A5018483662 @default.
• W2000366372 creator A5024889338 @default.
• W2000366372 creator A5029050145 @default.
• W2000366372 creator A5034732068 @default.
• W2000366372 creator A5037778424 @default.
• W2000366372 date "2014-03-01" @default.
• W2000366372 modified "2023-09-26" @default.
• W2000366372 title "Influence of βS-globin haplotypes hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia" @default.
• W2000366372 cites W13258977 @default.
• W2000366372 cites W137386777 @default.
• W2000366372 cites W1510833811 @default.
• W2000366372 cites W1893186436 @default.
• W2000366372 cites W1980024482 @default.
• W2000366372 cites W1985234047 @default.
• W2000366372 cites W1987986848 @default.
• W2000366372 cites W1991882047 @default.
• W2000366372 cites W1993847169 @default.
• W2000366372 cites W2001826981 @default.
• W2000366372 cites W2018617087 @default.
• W2000366372 cites W2023155433 @default.
• W2000366372 cites W2046052020 @default.
• W2000366372 cites W2053495832 @default.
• W2000366372 cites W2055152730 @default.
• W2000366372 cites W2055403900 @default.
• W2000366372 cites W2055848370 @default.
• W2000366372 cites W2092908345 @default.
• W2000366372 cites W2094865185 @default.
• W2000366372 cites W2097581338 @default.
• W2000366372 cites W2114403269 @default.
• W2000366372 cites W2125307800 @default.
• W2000366372 cites W2134233962 @default.
• W2000366372 cites W2143740873 @default.
• W2000366372 cites W2148674389 @default.
• W2000366372 cites W2163558908 @default.
• W2000366372 cites W2204302242 @default.
• W2000366372 cites W3144957394 @default.
• W2000366372 doi "https://doi.org/10.5581/1516-8484.20140028" @default.
• W2000366372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4005510" @default.
• W2000366372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24790537" @default.
• W2000366372 hasPublicationYear "2014" @default.
• W2000366372 type Work @default.
• W2000366372 sameAs 2000366372 @default.
• W2000366372 citedByCount "6" @default.
• W2000366372 countsByYear W20003663722014 @default.
• W2000366372 countsByYear W20003663722015 @default.
• W2000366372 countsByYear W20003663722018 @default.
• W2000366372 countsByYear W20003663722022 @default.
• W2000366372 crossrefType "journal-article" @default.
• W2000366372 hasAuthorship W2000366372A5016476003 @default.
• W2000366372 hasAuthorship W2000366372A5018483662 @default.
• W2000366372 hasAuthorship W2000366372A5024889338 @default.
• W2000366372 hasAuthorship W2000366372A5029050145 @default.
• W2000366372 hasAuthorship W2000366372A5034732068 @default.
• W2000366372 hasAuthorship W2000366372A5037778424 @default.
• W2000366372 hasBestOaLocation W20003663721 @default.
• W2000366372 hasConcept C104317684 @default.
• W2000366372 hasConcept C126322002 @default.
• W2000366372 hasConcept C135763542 @default.
• W2000366372 hasConcept C164027704 @default.
• W2000366372 hasConcept C172680121 @default.
• W2000366372 hasConcept C17991360 @default.
• W2000366372 hasConcept C197754878 @default.
• W2000366372 hasConcept C203014093 @default.
• W2000366372 hasConcept C2776317666 @default.
• W2000366372 hasConcept C2776914184 @default.
• W2000366372 hasConcept C2778248108 @default.
• W2000366372 hasConcept C2778620579 @default.
• W2000366372 hasConcept C2778917026 @default.
• W2000366372 hasConcept C2779134260 @default.
• W2000366372 hasConcept C2779234561 @default.
• W2000366372 hasConcept C54355233 @default.
• W2000366372 hasConcept C71924100 @default.
• W2000366372 hasConcept C86803240 @default.
• W2000366372 hasConcept C90924648 @default.
• W2000366372 hasConceptScore W2000366372C104317684 @default.
• W2000366372 hasConceptScore W2000366372C126322002 @default.
• W2000366372 hasConceptScore W2000366372C135763542 @default.
• W2000366372 hasConceptScore W2000366372C164027704 @default.
• W2000366372 hasConceptScore W2000366372C172680121 @default.
• W2000366372 hasConceptScore W2000366372C17991360 @default.
• W2000366372 hasConceptScore W2000366372C197754878 @default.
• W2000366372 hasConceptScore W2000366372C203014093 @default.
• W2000366372 hasConceptScore W2000366372C2776317666 @default.
• W2000366372 hasConceptScore W2000366372C2776914184 @default.
• W2000366372 hasConceptScore W2000366372C2778248108 @default.
• W2000366372 hasConceptScore W2000366372C2778620579 @default.
• W2000366372 hasConceptScore W2000366372C2778917026 @default.
• W2000366372 hasConceptScore W2000366372C2779134260 @default.
• W2000366372 hasConceptScore W2000366372C2779234561 @default.
• W2000366372 hasConceptScore W2000366372C54355233 @default.
• W2000366372 hasConceptScore W2000366372C71924100 @default.
• W2000366372 hasConceptScore W2000366372C86803240 @default.
• W2000366372 hasConceptScore W2000366372C90924648 @default.
• W2000366372 hasIssue "2" @default.
• W2000366372 hasLocation W20003663721 @default.

• next